Neuromodulation of Sleep and Mood: A Multimodal Biomarker Study of Non-Invasive Vagal Nerve Stimulation (MOSAIC-VNS)
University of Alabama at Birmingham
Summary
The purpose of this study is to learn how non-invasive cervical transcutaneous vagus nerve stimulation (ctVNS) - a treatment given by holding a small hand-held device against the right part of your neck (cervical vagus nerve) - affects sleep, heart rhythm, mood, and certain markers in the blood and some genetic material. The main questions it aims to answer are: 1. Will ctVNS enhance both subjective and objective sleep continuity and regularity, improve circadian stability, and increase parasympathetic HRV indices compared with the end-of-sham baseline? 2. Will improvements in HRV and sleep be associated with greater improvement in standardized depression ratings, with treatment effects mediated in part by improvements in sleep and in part by sleep-independent autonomic mechanisms? 3. Will ctVNS modify the expression of miRNAs related to sleep, stress, inflammation, and neuroplasticity, and baseline or early-change miRNA profiles, combined with physiological data, and may help distinguish responders from non-responders? This study lasts about 7 weeks. Participants will be asked to do the following: Visit 1/ Baseline (in person): * Participants will answer questions about their health, mood, and sleep; * have their blood pressure and pulse taken; * give about 28 mL (about 6 teaspoons) of blood - 20 mL for the research measurements and 8 mL for routine safety blood tests; * be fitted with a wrist device that measures your heart rate, physical activity and sleep; and be given the study device with training on how to use it at home. This visit will last about 2 hours. Weeks 1-6 (at home): * Participants will use the study device (nerve stimulator) twice a day (morning within 1 hour of waking, and evening within 1 hour of your usual bedtime), each use lasting about 2 minutes; * Participants will also need to wear the wrist device day and night; * Participants will fill out a short sleep diary each morning. Visit 2/ Week 2 (in person) and Visit 3/ Week 6 (in person): * Participants will repeat the questionnaires and interviews from Visit 1; * have their blood pressure and pulse taken; * give another blood sample of about 20 mL; * have the data from their wrist device downloaded. * At each in-person visit after visit 1, their study device will be checked and may be exchanged for another device. This visit will last about 1.5 - 2 hours. The investigators will call participants on the phone to check-in at Weeks 1, 3, and 5, and a safety call at Week 7. These phone calls will last about 15 minutes.
Description
Major depressive disorder (MDD) and insomnia are highly prevalent, frequently co-occur, and rank among the leading causes of disability worldwide. Up to 80% of people with MDD report significant sleep disturbance, and persistent insomnia predicts higher relapse, poorer treatment response, and greater functional impairment. Autonomic dysregulation, commonly indexed by reduced heart rate variability (HRV), is a shared feature of both conditions and a marker of poor outcome \[1\], alongside circadian disruption and neuroinflammatory signaling. Cervical transcutaneous vagus nerve stimulation (ctV…
Eligibility
- Age range
- 18–50 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * To be eligible, participants must meet all of the following criteria: 1. Adults aged 18 through 50 years, inclusive, at the time of consent. 2. Able to understand and provide written informed consent in English. 3. Willing and able to wear a study-provided wrist-worn device continuously for approximately 6 weeks and to complete daily sleep diaries. 4. Willing and able to self-administer the study device twice daily for 6 weeks and to complete a device use log. 5. Access to a smartphone compatible with the study wearable platform, or willingness to use a study-…
Interventions
- Deviceactive nVNS
ctVNS
- DeviceSham
sham run-in ctVNS
Location
- University of Alabama at Birmingham (UAB)Birmingham, Alabama